ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient ProgramBy Viropharma Incorporated, PRNE
Sunday, December 5, 2010
EXTON, Pennsylvania and WEYBRIDGE, England, December 6, 2010 - ViroPharma Incorporated (Nasdaq: VPHM) and Idis, the global leader in
developing long-term strategic solutions to therapeutic access, today
announced that the two companies have partnered to facilitate access to
certain ViroPharma products through a named patient program (NPP).
ViroPharma's NPP, developed and managed by Idis, will allow international
healthcare professionals to prescribe certain products to individual patients
until the time that approval is sought in local countries.
Under an NPP, physicians can prescribe investigational or pre-approval
products to qualifying patients on an individual basis. Such products can be
administered to individual patients who are suffering from serious illnesses
and have no other therapeutic options. Idis will manage the ViroPharma NPP in
countries, except the United States, where the products are not yet approved.
Licensed healthcare professionals in countries other than the United
States where such ViroPharma products are not yet approved, can access the
program at www.viropharmaNPP.com and on the physician section of the
ViroPharma Incorporated corporate website (www.viropharma.com), or can
contact Idis directly via telephone at +44(01)1952-824-100, fax
+44-(0)1932-824-300, or via email at firstname.lastname@example.org.
"This program was developed for certain patients who have no alternative
therapeutic option for their serious diseases," commented Thierry Darcis
M.D., vice president, general manager, ViroPharma Europe. "They are in great
need of access to investigational therapeutics that have either been approved
in other parts of the world or have shown promise in clinical studies, prior
to the time that regulatory approval is sought. ViroPharma is dedicated to
meeting the needs of patients, and the management of this NPP with our
partners Idis is consistent with that goal."
"The named patient program that we have developed for ViroPharma will
help ensure access to important therapies for patients with urgent unmet
medical needs. Idis will work in close partnership with ViroPharma to manage
named patient requests in a way that is reliable, responsible and legal,
ensuring the regulatory obligations are met," commented Simon Estcourt,
business development director, Idis.
About ViroPharma Incorporated
ViroPharma Incorporated is an international biopharmaceutical company
committed to developing and commercializing innovative products for physician
specialists to enable the support of patients with serious diseases for which
there is an unmet medical need, and providing rewarding careers to employees.
ViroPharma commercializes Cinryze(R) (C1 esterase inhibitor [human]) for
routine prophylaxis against angioedema attacks in adolescent and adult
patients with hereditary angioedema (HAE). ViroPharma commercializes
Vancocin(R), approved for oral administration for treatment of
antibiotic-associated pseudomembranous colitis caused by Clostridium
difficile and enterocolitis caused by Staphylococcus aureus, including
methicillin-resistant strains (for prescribing information on ViroPharma's
commercial products, please download the package inserts at
www.viropharma.com/Products.aspx). ViroPharma currently focuses its
drug development activities in diseases including C1 esterase inhibitor
deficiency and C. difficile.
ViroPharma routinely posts information, including press releases, which
may be important to investors in the investor relations and media sections of
our company's web site, www.viropharma.com/. The company encourages
investors to consult these sections for more information on ViroPharma and
Idis is the global long-term partner to pharmaceutical and biotech
companies, pharmacies and physicians. Making sure that the patient is at the
heart of everything we do, by developing long-term strategic solutions to
creating an understanding of and access to medicines around the globe,
enhancing life from different perspectives. Idis Named Patient Programmes
(NPPs) create access for the benefit of the patient. Corporate headquarter
based near central London, Idis has been a strategic partner to the world's
top 10 pharmaceutical and biotech companies. For more information on Idis,
please visit the website www.idispharma.com
ViroPharma, Kristina M. Broadbelt (Media), Assistant Director, PR & Advocacy, +1-610-321-2358; Idis, Rachel Scott, Brand Manager, +44(0)1932-824-134, rscott at idispharma.com
Tags: December 6, England, Exton, Pennsylvania, Pennsylvania And Weybridge, United Kingdom, Viropharma Incorporated